Lilly’s Omvoh is an IL23p19-targeting monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. Image credit: Tada Images / ...
Omvoh may increase the risk of infection. Do not initiate treatment with Omvoh in patients with a clinically important active infection until the infection resolves or is adequately treated.
Mirikizumab is approved for the treatment of moderately to severely active UC in adults and is marketed as Omvoh™. Mirikizumab has additional ongoing trials in UC, including a study in pediatric ...